Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

FDA clears Avails Medical AST system

March 2024—Avails Medical announced it has received FDA 510(k) clearance for its Equant system, an automated lab inoculation preparation system that consists of a single module instrument that holds a cuvette with an electrical sensor. It is intended for use with positive blood cultures samples for direct antimicrobial susceptibility testing without the traditional overnight subculture. The system works by preparing samples for direct susceptibility testing by manual agar disk diffusion.

Verichem reference materials for creatinine assays

March 2024—The Matrix Plus chemistry reference kit and standalone, ultra-high Matrix Plus level F for the calibration verification testing of creatinine assays by enzymatic and colorimetric methods are available from Verichem Laboratories. The ready-to-use reference materials offer constant protein content and pH across all concentration levels. The five-level Matrix Plus kit and level F feature a creatinine range from 0.2 mg/dL to 30.0 mg/dL and are intended to be treated as patient specimens. Shelf life and open-vial stability are 21 months from the manufacturing date.

Randox releases bladder cancer array

March 2024—Randox has released its female bladder cancer array, designed to help clinicians stratify patients presenting with hematuria. The array detects interleukin-12p70, interleukin-13, midkine, and clusterin from a single urine sample to determine an individual’s biomarker risk score. A person’s risk for developing bladder cancer is determined by combining the biomarker risk score with clinical risk scores generated using the company’s algorithms.

Bruker to acquire EliTechGroup

March 2024—Bruker Corp. has entered into a definitive share purchase agreement to acquire EliTechGroup for €870 million (about $940 million) in cash, excluding EliTech’s clinical chemistry business. Bruker expects to close the transaction in the second quarter of this year.

Roche to acquire LumiraDx’s POC technology

March 2024—Roche has entered into a definitive agreement to acquire select parts of the LumiraDx group related to LumiraDx’s point-of-care technology. The transaction is expected to close by the middle of this year, after which the acquired entities will be fully integrated into Roche Diagnostics.

FDA clears EDTA cartridges for SeptiCyte Rapid

March 2024—Immunexpress announced FDA clearance of EDTA blood compatible cartridges for use with the SeptiCyte Rapid test. SeptiCyte Rapid is a sample-to-answer, cartridge-based, host response molecular test for sepsis using reverse transcription polymerase chain reaction to quantify the relative expression levels of host response genes isolated from whole blood. It is intended for in vitro diagnostic use and runs on the Biocartis Idylla platform.

Binx, Cardinal Health enter into distribution agreement

March 2024—Binx Health announced it has entered into a national distribution agreement with Cardinal Health to expand access to care with its CLIA-waived, FDA-cleared Binx IO. The molecular point-of-care platform is used to detect chlamydia and gonorrhea in male and female patient samples and provides results in about 30 minutes.

Cepheid gets CLIA waiver for Xpert Xpress MVP

March 2024—Cepheid announced it has received FDA clearance with a CLIA waiver for the Xpert Xpress MVP, a multiplex vaginal panel that can now be performed in near-patient settings. The test is intended to aid in the diagnosis of bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis from a single specimen. It runs on Cepheid’s GeneXpert Xpress instruments and provides results within an hour.

OGT expands NGS operations in the U.K.

March 2024—OGT announced the opening of state-of-the-art facilities in Oxford Technology Park in the U.K. The facilities will drive development of OGT’s SureSeq next-generation sequencing product portfolio, as well as deliver expert-led training and opportunities for collaboration. Customers can receive face-to-face support with OGT’s field application specialists at the new facility and in-depth demonstrations of the company’s NGS and FISH products.

Copan gets third clearance for Colibrí system

March 2024—Copan Diagnostics announced the third FDA 510(k) clearance for its Colibrí automated ID/AST preparation instrument. The in vitro diagnostic specimen preparation system has been cleared to prepare MALDI-TOF targets for qualitative identification and microbial suspension for the Beckman Coulter MicroScan WalkAway antimicrobial susceptibility testing system for qualitative testing of isolated colonies of Gram-negative and Gram-positive bacterial species grown on solid culture media.

MARKETPLACE

TRENDING